Compare OVID & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OVID | IVVD |
|---|---|---|
| Founded | 2014 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 522.6M | 437.1M |
| IPO Year | 2017 | 2021 |
| Metric | OVID | IVVD |
|---|---|---|
| Price | $2.26 | $0.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.60 | ★ $8.75 |
| AVG Volume (30 Days) | 1.5M | ★ 3.9M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.90 | ★ 79.02 |
| EPS | N/A | ★ N/A |
| Revenue | $7,252,000.00 | ★ $53,426,000.00 |
| Revenue This Year | N/A | $61.57 |
| Revenue Next Year | $19.34 | $41.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1181.27 | 110.47 |
| 52 Week Low | $0.29 | $0.49 |
| 52 Week High | $3.11 | $3.07 |
| Indicator | OVID | IVVD |
|---|---|---|
| Relative Strength Index (RSI) | 39.64 | 24.13 |
| Support Level | $1.95 | N/A |
| Resistance Level | $2.38 | $1.25 |
| Average True Range (ATR) | 0.17 | 0.10 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 14.97 | 8.34 |
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.